Rubicon Founders Invests in Horizon Infusions
BroadOak Capital Partners is pleased to share that Rubicon Founders has invested in Horizon Infusions. BroadOak has supported Horizon Infusions for several years as the company grew from a single location to nearly two-dozen. With increased interest and support, Horizon Infusions’ excellent team and business model will continue to scale to meet growing customer demand. […]
Werfen acquires Omixon
BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately held company based in Budapest, Hungary, develops and commercializes NGS technology for transplant diagnostics. The full press release is below. October 16, 2024 (Barcelona, Spain): Werfen announced today that it has completed the acquisition of Omixon after obtaining all […]
LabConnect Acquires A4P Bio
BroadOak Capital Partners advised LabConnect on its acquisition of A4P Bio. A4P Bio provides bioanalytical project management solutions and consultancy for clinical trials. The full press release is below. JOHNSON CITY, Tenn., April 22, 2024 /PRNewswire/ — LabConnect has announced the acquisition of A4P Consulting Ltd (A4P), a scientific consultancy company, specializing in bioanalytical and biosample project […]
ZoBio Sells to Oncodesign Services
BroadOak Capital Partners advised ZoBio on the sale of the company to Oncodesign Services. ZoBio is a leading provider of biophysics-based small molecule drug discovery services. The full press release is below. Dijon, France & Leiden, The Netherlands, January 23rd, 2024 – Oncodesign Services (ODS), a leading Contract Research Organization specialized in drug discovery and […]
BRT Sells to Medix Biochemica
BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica. BRT is a leading provider of high-quality base matrices and other critical raw materials for the IVD industry. The full press release is below. Bioresource Technology joins Medix Biochemica Group Medix Biochemica broadens its capabilities in diagnostic base matrices […]
Biosynth Carbosynth Acquires Aalto Bio Reagents
BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a KKR and Ampersand portfolio company. The full press release is below. Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. Staad, 25 May 2022 – Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to […]
BroadOak Q1 2022 M&A Newsletter
BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 1Q 2022 BroadOak M&A Newsletter.
BroadOak Q4 2021 M&A Newsletter
BroadOak’s Q4 Quarterly Review analyzes market trends and M&A deals across life sciences tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 4Q 2021 BroadOak M&A Newsletter.
Rockland Acquires Antibodies-Online
Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners. Bill Snider, Partner at BroadOak Capital Partners commented: “We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland is a highly respected and innovative business that has […]
KCAS Acquires FlowMetric
BroadOak Partners advised KCAS, a Vitruvian Partners portfolio company, on the acquisition of FlowMetric, LLC. FlowMetric is a leading provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell and gene therapy industries. The full press release is below. KCAS Bioanalytical and Biomarker Services, a Vitruvian Partners portfolio Company, announces acquisition […]